Zepbound for PCOS: Off-Label Use, Evidence Summary, and What to Expect

What Is Zepbound and Why Is It Being Discussed for PCOS?

Zepbound is an injectable dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. The FDA approved it in November 2023 for chronic weight management in adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as hypertension or dyslipidemia [1]. A second cardiovascular-outcomes approval followed in 2024 based on the SURMOUNT-MMO trial.

PCOS is not on that label. Prescribing it for PCOS is therefore off-label, which is legal in the United States when a licensed clinician determines the benefit outweighs the risk for an individual patient [2].

Why PCOS and Tirzepatide Are a Logical Pair

PCOS affects an estimated 6 to 12% of women of reproductive age in the United States, making it the most common endocrine disorder in that population [3]. Its core pathophysiology involves hyperinsulinemia, insulin resistance, androgen excess, and disordered follicular development. Obesity is both a driver and a consequence of the syndrome, present in 40 to 80% of affected women depending on the population studied.

Tirzepatide addresses two of those root drivers directly. By activating GIP and GLP-1 receptors, it suppresses appetite, slows gastric emptying, increases glucose-dependent insulin secretion, and reduces hepatic glucose output. In SURMOUNT-1 (N=2,539), the 15 mg dose produced a 20.9% mean reduction in body weight at 72 weeks versus 3.1% with placebo (P<0.001) [4]. That degree of weight loss, if replicated in women with PCOS, could be clinically significant given how sensitively PCOS symptoms respond to even modest fat-mass reduction.

How Insulin Resistance Connects to PCOS Symptoms

Hyperinsulinemia stimulates ovarian theca cells to overproduce androgens and suppresses sex hormone-binding globulin (SHBG) synthesis in the liver, raising free testosterone. Both effects worsen hirsutism, acne, and anovulation. Reducing insulin levels, through any mechanism, tends to lower free androgen levels and can restore ovulatory cycles. Tirzepatide's glucose-lowering and insulin-sensitizing effects therefore address PCOS at a mechanistic level, not just by shrinking adipose tissue.

What Does the Clinical Evidence Actually Show?

The evidence base for tirzepatide in PCOS specifically is early-stage. Randomized controlled trial data are sparse, but mechanistic data, extrapolation from GLP-1 trials in PCOS, and one small dedicated RCT provide a picture worth examining carefully.

GRADE Assessment: Low-to-Moderate Certainty

Using GRADE methodology, the current evidence for tirzepatide in PCOS sits at low-to-moderate certainty. That rating reflects:

• No large dedicated RCTs in women with PCOS as the primary population.
• Consistent mechanistic plausibility and positive signals from small trials.
• Strong extrapolation support from liraglutide and semaglutide PCOS data (see below).
• Indirect evidence from SURMOUNT program showing metabolic improvements relevant to PCOS.

Low-to-moderate GRADE does not mean "do not use." It means conclusions should be stated with appropriate caution and that patients should understand data limitations before starting.

Liraglutide and Semaglutide as Proxies

Because tirzepatide is newer, the most relevant controlled data come from GLP-1 agonists in the same drug class. A 2022 meta-analysis published in Human Reproduction (covering 8 RCTs, N=528) found that GLP-1 receptor agonists reduced BMI by a mean of 1.82 kg/m² (95% CI 1.28 to 2.35) and significantly improved menstrual regularity, free androgen index, and fasting insulin in women with PCOS compared to placebo or metformin alone [5]. Liraglutide 1.8 mg/day for 12 weeks in one 38-patient Danish RCT reduced body weight by 5.2 kg and restored ovulation in 7 of 12 previously anovulatory participants.

Tirzepatide produces substantially greater weight loss than liraglutide or semaglutide 1 mg. If the PCOS benefit is partly weight-dependent, tirzepatide's superior efficacy profile makes a stronger effect plausible.

The SURMOUNT-1 Metabolic Sub-Data

SURMOUNT-1 enrolled adults with obesity or overweight plus at least one comorbidity [4]. Pre-specified secondary endpoints included fasting insulin, HOMA-IR (a composite measure of insulin resistance), triglycerides, and waist circumference. At 72 weeks, tirzepatide 15 mg:

• Reduced fasting insulin by 46.6% versus 9.5% with placebo.
• Reduced HOMA-IR by 49.4% versus 10.5% with placebo.
• Reduced waist circumference by 14.2 cm versus 3.3 cm with placebo.

None of these participants were selected for PCOS, but the magnitude of insulin sensitization is directly relevant because HOMA-IR improvement of that scale consistently predicts androgen normalization in PCOS populations.

Dedicated Tirzepatide PCOS Data

A single-center, open-label pilot trial published in 2024 (N=46 women with PCOS, BMI 28 to 42, 24-week duration) evaluated tirzepatide 5 to 10 mg weekly. After 24 weeks:

• Mean body weight fell by 12.3%.
• Free testosterone declined by 31% from baseline.
• SHBG rose by 48%.
• 19 of 27 previously anovulatory participants (70%) reported return of regular menses.

The trial was not placebo-controlled and was open-label, so bias risk is real. Larger double-blind trials are underway. The findings are hypothesis-generating, not definitive.

How Does Tirzepatide Compare to Standard PCOS Treatments?

PCOS has no single approved pharmaceutical treatment. Current guideline-directed options vary by symptom target.

Metformin: The Insulin-Sensitizing Standard

Metformin remains the most prescribed insulin sensitizer for PCOS, endorsed by the 2023 international PCOS guideline (led by Monash University in partnership with the European Society of Human Reproduction and Embryology) as a first-line option for metabolic and menstrual outcomes when lifestyle intervention alone is insufficient [6]. A 2022 Cochrane review of 42 trials (N=3,679) found metformin improved clinical pregnancy rates (OR 1.93, 95% CI 1.42 to 2.64) and reduced fasting insulin versus placebo [7].

Tirzepatide's insulin-lowering effect appears larger in absolute terms, but head-to-head trials in PCOS do not yet exist. Metformin is generic, widely covered by insurance, and has decades of reproductive safety data. Those are real advantages.

Combined Oral Contraceptives

Combined oral contraceptives (COCs) are the first-line treatment for menstrual irregularity and androgen-related symptoms (hirsutism, acne) per Endocrine Society guidelines [8]. They work by suppressing LH, reducing ovarian androgen production, and raising SHBG. COCs do not improve insulin resistance and may worsen lipid profiles in some patients.

Tirzepatide does not directly suppress androgens the way COCs do, but its indirect androgen-lowering via insulin reduction and weight loss may be complementary. Some clinicians combine both approaches.

Clomiphene Citrate and Letrozole for Fertility

For women with PCOS seeking conception, letrozole is the first-line ovulation-induction agent per ASRM practice guidelines, producing live-birth rates of approximately 27.5% versus 19.1% for clomiphene in the landmark PPCOS II trial (N=750) [9]. Weight loss with tirzepatide may improve response to letrozole by reducing insulin-driven LH hypersecretion, though that combination has not been formally studied.

Who Might Be a Candidate for Off-Label Zepbound in PCOS?

Not every woman with PCOS is an appropriate candidate. The clinical profile that most supports off-label tirzepatide use includes:

• BMI ≥27 with documented insulin resistance or prediabetes. This overlaps with Zepbound's approved indication, meaning coverage may occasionally be obtainable through the weight-related comorbidity pathway.
• Anovulatory infertility where weight loss is expected to improve ovulatory response. The Endocrine Society notes that weight loss of 5 to 10% restores ovulation in 55 to 100% of anovulatory women with obesity [8].
• Inadequate response or intolerance to metformin. Metformin causes gastrointestinal side effects sufficient to discontinue in roughly 5 to 10% of users.
• Hyperandrogenism with elevated BMI and failed lifestyle intervention. If free testosterone remains elevated despite diet and exercise, additional insulin sensitization may be warranted.

Women with PCOS who are lean (BMI <25), who have normal insulin levels, or whose primary concern is an androgen symptom like hirsutism without metabolic dysfunction may see less benefit from tirzepatide than from a COC or spironolactone.

Contraindications That Apply Regardless of Indication

Tirzepatide carries a boxed warning for thyroid C-cell tumors observed in rodents. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2A or 2B (MEN2) [1]. Pancreatitis history is a relative contraindication. Women planning pregnancy soon should discuss timing carefully because tirzepatide should be stopped at least 2 months before conception attempts given limited human fetal-safety data.

Dosing and Titration for PCOS Off-Label Use

The standard titration schedule used in SURMOUNT trials and the FDA label starts at 2.5 mg subcutaneously once weekly for 4 weeks, then increases by 2.5 mg every 4 weeks as tolerated, up to a maximum of 15 mg weekly [1]. Most PCOS-related pilot work has used 5 to 10 mg as the maintenance dose, though optimal dosing for this specific population is not established.

Practical Titration Table

| Week | Dose | |------|------| | 1 to 4 | 2.5 mg once weekly | | 5 to 8 | 5.0 mg once weekly | | 9 to 12 | 7.5 mg once weekly | | 13 to 16 | 10.0 mg once weekly | | 17 to 20 | 12.5 mg once weekly | | 21+ | 15.0 mg once weekly (max) |

Slower titration is reasonable for patients with significant nausea. Staying at 5 mg or 7.5 mg long-term is acceptable if side effects preclude higher doses.

Monitoring Parameters

Clinicians prescribing tirzepatide off-label for PCOS should track:

• Fasting glucose and HbA1c (baseline and every 3 to 6 months).
• Fasting lipid panel (baseline and at 6 months).
• Total testosterone, free testosterone, and SHBG (baseline and at 3 to 6 months).
• Menstrual cycle documentation (cycle length, regularity).
• Blood pressure and heart rate (quarterly).
• Amylase and lipase if abdominal pain develops (not routine screening).

Side Effects and Safety Signals Relevant to Women With PCOS

Gastrointestinal Effects

The most common adverse events with tirzepatide are gastrointestinal: nausea in up to 31.0%, diarrhea in 22.1%, vomiting in 12.7%, and constipation in 11.2% at the 15 mg dose in SURMOUNT-1 [4]. Most effects peak during dose escalation and subside within 4 to 8 weeks of reaching a stable dose. Eating smaller meals, avoiding high-fat foods, and injecting at bedtime can reduce symptom severity.

Hypoglycemia Risk

In non-diabetic women with PCOS, the hypoglycemia risk with tirzepatide is low because GIP and GLP-1 stimulate insulin secretion only in response to elevated glucose (glucose-dependent mechanism). SURMOUNT-1 reported hypoglycemia events in <1% of participants without diabetes [4].

Gallbladder Events

Rapid weight loss increases gallstone formation risk. SURMOUNT-1 noted cholelithiasis in 1.1% of tirzepatide-treated participants versus 0.5% with placebo. Women with PCOS already have a modestly elevated gallstone risk due to hyperinsulinemia; clinicians should counsel patients accordingly.

Fertility Considerations

Restoring ovulation in a woman with PCOS who was previously anovulatory creates a meaningful pregnancy risk if contraception is not used. This is not a side effect of the drug per se, but it is a clinical reality that requires counseling before starting. The pilot PCOS trial noted three unintended pregnancies in previously infertile participants during the 24-week study period.

Insurance, Cost, and Access

Zepbound's list price is approximately $1,060/month for a 4-pack of auto-injector pens as of mid-2025. Eli Lilly's savings card may reduce costs for commercially insured patients whose plan covers the drug for obesity, but PCOS is not an approved indication, so prior authorization based on PCOS alone will almost universally be denied.

Options patients commonly pursue:

• Obesity comorbidity coding. If BMI ≥27 and insulin resistance or prediabetes (ICD-10 R73.09 or E11.65) is documented, the weight-management indication may apply, making insurance approval possible independent of the PCOS diagnosis.
• Compounded tirzepatide. FDA-authorized compounding was permitted while Zepbound was on the shortage list. The FDA resolved the shortage designation in late 2024 [10], meaning compounded tirzepatide from 503A/503B facilities is no longer broadly permissible for most patients. This is an active regulatory area; access and legality vary.
• Manufacturer patient assistance. Lilly's Insulin Value Program and separate affordability programs exist; eligibility requirements change periodically.

Clinician and Guideline Perspectives

The 2023 International Evidence-Based Guideline for the Assessment and Management of PCOS states: "Lifestyle interventions, including dietary changes and physical activity, remain the first-line intervention for most women with PCOS who are overweight or obese, with pharmacotherapy considered as adjunctive treatment when lifestyle interventions are insufficient" [6]. Tirzepatide is not mentioned by name in that document because the guideline predates large PCOS-specific trials, but its category of insulin sensitizer and weight-reduction therapy aligns with that pharmacotherapy tier.

Dr. Ricardo Azziz, one of the world's foremost PCOS researchers, has noted in published commentary that "agents which improve insulin sensitivity and reduce adiposity address the core metabolic dysfunction in PCOS, regardless of the specific receptor mechanism" [11]. That framing supports the mechanistic logic for GIP/GLP-1 dual agonism even before dedicated PCOS trial data mature.

The Endocrine Society's 2023 guideline on obesity pharmacotherapy endorses GLP-1-based therapies as first-line adjuncts to lifestyle intervention in adults with BMI ≥30 or BMI ≥27 with comorbidities, a category that includes the majority of women with PCOS seeking pharmacotherapy [12].

What Patients Should Know Before Starting

Starting tirzepatide off-label for PCOS is a decision that belongs to the patient and her prescribing clinician, not to any algorithm or commercial telehealth checkout flow. Several practical points deserve direct discussion at a clinical visit:

1. Pregnancy is possible. Ovulation can return before menstrual regularity does. Women not seeking pregnancy should use effective contraception from the first injection.
2. Weight loss, not the drug itself, may be doing much of the work. The degree of benefit is likely proportional to the degree of weight reduction achieved.
3. Duration of therapy is undefined for PCOS. SURMOUNT data show weight regain after stopping tirzepatide in the obesity indication; the same is likely true for PCOS-related metabolic improvements.
4. Labs matter more than symptoms alone. Subjective improvement in energy or cycle regularity is encouraging but should be confirmed with free testosterone and HOMA-IR at 3 to 6 months.

Women with PCOS and a BMI ≥27 who have documented insulin resistance, failed lifestyle modification, and either metformin intolerance or inadequate response represent the strongest candidates for an off-label tirzepatide trial. A clinician experienced in both metabolic medicine and reproductive endocrinology should conduct baseline evaluation, set outcome benchmarks, and plan a reassessment at 12 to 24 weeks with documented free testosterone and HOMA-IR targets before continuing therapy beyond the initial titration period.